Drugs / MK-8242
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01463696 | Dec 2011 → Sep 2014 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01451437 | Nov 2011 → Sep 2014 | acute myeloid leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01463696 ↗ |
| Action | Inhibit | “A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).” PMID 27544076 ↗ Jul 2016 |
| Route | Oral | “MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle” NCT01451437 ↗ |
| Target | MDM2 | “A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).” PMID 27544076 ↗ Jul 2016 |